Login / Signup

Real-world effectiveness, drug survival and safety of risankizumab over a period of 2 years in 158 patients with moderate-to-severe plaque psoriasis.

Natalia RompotiIrene StefanakiPantelis PanagakisMarina PapoutsakiMaria PolitouCharitomeni VavouliAngeliki BefonFiori KoustaEleni LazouMaria ZaimiIoannis-Alexios KoumprentziotisVasiliki ChasapiDimitrios RigopoulosAlexander StratigosElectra Nicolaidou
Published in: Journal of the European Academy of Dermatology and Venereology : JEADV (2024)
Keyphrases
  • randomized controlled trial
  • systematic review
  • drug induced
  • coronary artery disease
  • high intensity
  • early onset
  • free survival
  • adverse drug
  • atopic dermatitis
  • emergency department